ALK ( ALKB:DC / OMX: ALK B) today announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical Co. Ltd. (“GenSci”) to develop and commercialise ALK’s house dust mite (“HDM”) ...

The original anhydrous form of buntanetap has been used in all preclinical and clinical studies to date. Recently, the ...

Brewed by Oregon’s Hop Valley with premium Cryo Hops®, Dang Green is a smooth 7.0% ABV IPA that delivers bold West Coast ...

Commure, a leading healthcare technology company, today announced the seamless integration and direct embedding of its ...

The Phase 1 SPARC trial will evaluate the safety, tolerability, and pharmacokinetics of OPT101 in patient volunteers. The data will inform future studies in patients with advanced CKD (chronic kidney ...

Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune ...

EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary ...

New Life, a Marbella-based leader in executive recovery and holistic wellness, has announced the expansion of its flagship Prestige programme into the Middle East. In partnership with Aims Healthcare, ...

Pursuant to the terms of the securities purchase agreement, Oruka is selling an aggregate of (i) 10,933,405 shares of its common stock (“Common Stock”) at a purchase price of $15.00 per share and (ii) ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a ...

Robust Preclinical Activity: In a broad panel of genetically-defined, in vivo tumor models, FTIs potently suppress mTOR signaling, driving enhanced anti-tumor activity when combined with ...